Login to Your Account



SALIX: ACCESS FOR PATIENTS LATER THIS YEAR

Pharming's Ruconest wins FDA nod in crowded orphan HAE market

By Jennifer Boggs and Cormac Sheridan
Staff Writers

Friday, July 18, 2014
As expected, the FDA cleared for marketing Wednesday recombinant human C1 esterase inhibitor Ruconest (conestat alpha) for use in acute attacks of hereditary angioedema (HAE), news that should bring an immediate lift to developer Pharming Group NV – in the form of a $20 million milestone payment from partner Salix Pharmaceuticals Inc. due upon the first U.S. sale – but offers little clarity as to how the drug will stack up against well-entrenched competitors in the crowded HAE space.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription